Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Results 1 - 20 of 58 : 1 2 3 Next »

Recs

0
Member Avatar liebezeit2 (55.65) Submitted: 6/9/2014 5:17:37 PM : Outperform Start Price: $4.38 NVAX Score: -1.84

Immediate need for new vaccines worldwide.

Recs

0
Member Avatar otherAquanaut (99.80) Submitted: 3/17/2014 1:43:06 PM : Outperform Start Price: $1.32 NVAX Score: +192.02

It's started trending down. Keep an eye on it.

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/15/2014 9:57:07 AM : Outperform Start Price: $3.99 NVAX Score: +3.62

BP $5 TP $11 REV 3YR 250% 5YR 1140%

Recs

0
Member Avatar biznessdoc (59.14) Submitted: 1/22/2014 2:01:07 PM : Outperform Start Price: $5.98 NVAX Score: -34.72

The company to OWN in emerging vaccines.

Recs

0
Member Avatar bluesteel22 (< 20) Submitted: 12/17/2013 4:49:23 PM : Outperform Start Price: $4.48 NVAX Score: -13.51

Its been a beast in the past few months and I'm going with the crowd of analysts on this. Do I know about phase 2 and 3 trails and what's going on in China? Nope. But mom said if all your friends jumped off a building would you? Yep. If we all land in a big pile of cash.

Recs

0
Member Avatar zincfinger (< 20) Submitted: 11/16/2013 5:37:26 PM : Outperform Start Price: $3.15 NVAX Score: +29.08

NVAX can go from viral sequence to first doses of vaccine within 12 weeks, 50 million doses within four months, and hundreds of millions of doses within six months. Non egg production (no supply problem, no problem handling avian influenzas) NOT a live vaccine
NVAX's VLP technology highly effective in all clincial trials so far. Influenza vaccines high cross reactivity with other influenzas.
RSV vaccine($billion+ annual market) >4 years ahead of all others. No competition in that market

Cash for two years burn rate

Potential for multi stockpile orders for H7N9 vaccine (and a MERS vaccine in the works)

"Outperform" too weak but no higher option!

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:35:38 PM : Underperform Start Price: $2.90 NVAX Score: -31.91

Short. Biopharma losing lots of money and issuing more and more stock.

Recs

0
Member Avatar Bioguy65 (70.97) Submitted: 6/22/2013 4:44:12 PM : Outperform Start Price: $1.90 NVAX Score: +111.41

I like this long term but also at times for trading. With the MERS coronavirus scare and fact that NVAX has already produced their MERS vaccine candidate, this should be a very good two weeks to own this stock.

Recs

1
Member Avatar Igasu (< 20) Submitted: 12/28/2012 6:02:09 PM : Outperform Start Price: $1.81 NVAX Score: +100.49

NVAX has new homogenate to make its patented Viral Like Particles that uses insect homogenate v eggs. (Currently takes about a billion eggs/yr to make our flu vaccine) Factories are much cheaper to build. The hysteresis from virus to vaccine is half the time of conventional vaccines. They have an RSV vaccine that appears to be very immunogenic. (The only one out there right now)

Recs

0
Member Avatar ftsmd (< 20) Submitted: 7/8/2012 8:13:08 PM : Outperform Start Price: $1.97 NVAX Score: +76.12

It is now on the rise. Flu season is just around the corner and its vaccines for the prevention of RSV and pneumonia have been showing promising results in their trials.

Recs

0
Member Avatar RBuskey106 (45.11) Submitted: 3/21/2012 8:28:35 PM : Outperform Start Price: $1.33 NVAX Score: +188.13

Bio stock

Recs

0
Member Avatar TXKL (< 20) Submitted: 3/16/2012 2:46:00 PM : Outperform Start Price: $1.37 NVAX Score: +179.68

No genius info here. If they can get something approved by the FDA they will skyrocket.

Recs

0
Member Avatar mgm4 (< 20) Submitted: 8/30/2011 2:55:16 PM : Outperform Start Price: $1.91 NVAX Score: +66.65

Flu season...media...paranoia

Recs

0
Member Avatar cecamadocv1 (99.97) Submitted: 8/30/2011 1:36:38 PM : Outperform Start Price: $1.94 NVAX Score: +62.16

Im just following the crowd on this one. Insider buying, sitting on money. Things are looking good... So why not?

Recs

0
Member Avatar Lawrence56 (< 20) Submitted: 3/18/2011 1:46:03 PM : Outperform Start Price: $2.56 NVAX Score: +16.20

2yr gov contract with possible extension of 2 additional

Recs

0
Member Avatar TrafficDesign (24.58) Submitted: 12/16/2010 8:57:50 AM : Outperform Start Price: $2.87 NVAX Score: -26.12

Finally......

Novavax, Inc. NVAX announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. Dr. Rahul Singhvi, President and CEO of Novavax says, "This is a significant accomplishment and represents the second major internally discovered vaccine program based on our core platform technologies. RSV is the leading cause of viral death in infants and a common illness in elderly adults. A safe and effective vaccine is especially needed in these populations since RSV infection does not provoke lasting immunity." In the United States alone, hospitalizations due to RSV results in annual medicals costs exceeding $1 billion.

Orignally I was RED thumb on this company, but they have had some great growth in the research field and seem to have goals set in place with clear direction. FDA clearance on anything these days is like gold, and I doubt they will screw it up. Because of this I stick with my GREEN thumb prediction and wish the company the best of luck. If they come out with new and better vaccines each year, I think we will have a real winner on our hands.

Recs

0
Member Avatar Ellas77 (< 20) Submitted: 11/26/2010 1:08:03 PM : Outperform Start Price: $2.24 NVAX Score: +27.95

Extremely low price x low market capitalization + winter = increased share price

Recs

0
Member Avatar ah6br (< 20) Submitted: 5/10/2010 4:58:12 PM : Outperform Start Price: $2.67 NVAX Score: -8.87

New vaccine technology.

Recs

0
Member Avatar sujoypaul (< 20) Submitted: 5/4/2010 3:07:14 PM : Outperform Start Price: $2.69 NVAX Score: -6.47

BARDA contract, Mexico approval. Final stage of US FDA Phase III

Recs

0
Member Avatar JLuz (33.69) Submitted: 9/28/2009 2:16:02 PM : Underperform Start Price: $4.37 NVAX Score: +87.71

can't believe this is still going up. Re-entering thumbs down. Swine flu... are you kidding me?

Results 1 - 20 of 58 : 1 2 3 Next »

Featured Broker Partners


Advertisement